Paris, France

Isabelle Vigon

This inventor holds 2 USPTO granted patents. Top assignee: National Institute of Health and Medical Research. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Isabelle Vigon

Introduction

Isabelle Vigon is a prominent inventor based in Paris, France. She has made significant contributions to the field of molecular detection and growth factor receptors. With a total of 2 patents, her work has implications in both research and medical diagnostics.

Latest Patents

Isabelle Vigon's latest patents include innovative methods for the detection of molecules with affinity for MPL polypeptides. These polypeptides are part of a growth factor receptor family and possess specific sequences that encourage and/or are involved in the proliferation and/or differentiation of hematopoietic cell lines when derived from the MPLV retrovirus. Additionally, her patents describe a nucleic acid encoding polypeptide of a growth factor receptor family, which has applications in diagnosing the expression of the ligand polypeptide.

Career Highlights

Isabelle Vigon is affiliated with the National Institute of Health and Medical Research, where she conducts her research and develops her inventions. Her work is crucial in advancing our understanding of hematopoietic growth factors and their receptors.

Collaborations

Isabelle has collaborated with notable colleagues such as Sylvie Gisselbrecht and Michele Souyri. Their combined expertise enhances the impact of their research in the scientific community.

Conclusion

Isabelle Vigon's innovative work in the field of molecular detection and growth factor receptors showcases her significant contributions to science and medicine. Her patents reflect her dedication to advancing research and improving diagnostic methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…